Atypical teratoid rhabdoid tumors (ATRTs): The British Columbia's Children's Hospital's experience, 1986-2006

Brain Pathology

Volumn 22, Issue 5, 2012, Pages 625-635

  Fleming, Adam J ^a   Hukin, Juliette ^a   Rassekh, Rod ^a   Fryer, Christopher ^a   Kim, James ^b   Stemmer Rachamimov, Anat ^b   Birks, Diane K ^c   Huang, Annie ^d,f   Yip, Stephen ^e   Dunham, Christopher ^a  

^a BC CHILDREN S HOSPITAL   (Canada)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c CHILDREN S HOSPITAL COLORADO   (United States)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

atypical teratoid rhabdoid tumor (ATRT); claudin 6; epigenetics; INI 1; methylation specific PCR (MSP); MGMT

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PREDNISONE; VINCRISTINE;

ARTICLE; ATYPICAL TERATOID RHABDOID TUMOR; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANADA; CHILD; CLDN6 GENE; CLINICAL ARTICLE; DNA METHYLATION; EPIGENETICS; FEMALE; FRAMESHIFT MUTATION; GENE; GENE EXPRESSION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; PEDIATRIC HOSPITAL; PHENOTYPE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PROMOTER REGION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOID TUMOR; SCHOOL CHILD; SPLICING DEFECT; SURVIVOR; TERATOMA;

BRITISH COLUMBIA; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; CLAUDINS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GENETIC TESTING; HOSPITALS, PEDIATRIC; HUMANS; INFANT; MALE; MUTATION; RETROSPECTIVE STUDIES; RHABDOID TUMOR; TERATOMA; TUMOR SUPPRESSOR PROTEINS;

EID: 84865503135     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2011.00561.x     Document Type: Article

References (44)

1. Antonelli M, Hasselblatt M, Haberler C, Di Giannatale A, Garre ML, Donofrio V, et al, (2011) Claudin-6 is of limited sensitivity and specificity for the diagnosis of atypical teratoid/rhabdoid tumors. Brain Pathol 21: 558-563.
2. Athale UH, Duckworth J, Odame I, Barr R, (2009) Childhood atypical teratoid rhabdoid tumor of the central nervous system: a meta-analysis of observational studies. J Pediatr Hematol Oncol 31: 651-663.
3. Biegel JA, Tan L, Zhang F, Wainwright L, Russo P, Rorke LB, (2002) Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clin Cancer Res 8: 3461-3467. (Pubitemid 35340722)
4. Birks DK, Kleinschmidt-DeMasters BK, Donson AM, Barton VN, McNatt SA, Foreman NK, Handler MH, (2009) Claudin 6 is a positive marker for atypical teratoid/rhabdoid tumors. Brain Pathol 20: 140-150.
5. Birks DK, Donson AM, Patel PR, Dunham C, Muscat A, Algar EM, et al, (2011) High expression of BMP pathway genes distinguishes a subset of atypical teratoid/rhabdoid tumors associated with shorter survival. Neuro Oncol 13: 1296-1307.
6. Bourdeaut F, Freneaux P, Thuille B, Lellouch-Tubiana A, Nicolas A, Couturier J, et al, (2007) hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities. J Pathol 211: 323-330. (Pubitemid 46172708)
7. Burger PC, Yu IT, Tihan T, Friedman HS, Strother DR, Kepner JL, et al, (1998) Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. Am J Surg Pathol 22: 1083-1092. (Pubitemid 28411066)
8. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, et al, (2007) Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 13: 2038-2045. (Pubitemid 46649870)
9. Cannavo E, Marra G, Sabates-Bellver J, Menigatti M, Lipkin SM, Fischer F, et al, (2005) Expression of the MutL homologue hMLH3 in human cells and its role in DNA mismatch repair. Cancer Res 65: 10759-10766. (Pubitemid 41713344)
10. Central Brain Tumor Registry of the United States (CBTRUS) (2009) Statistical Report: Primary Brain Tumors in the United States, 2002-2006. Central Brain Tumor Registry of the United States: Hinsdale, IL.
11. Chi SN, Zimmerman MA, Yao X, Cohen KJ, Burger P, Biegel JA, et al, (2009) Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol 27: 385-389.
12. Dong SM, Kim HS, Rha SH, Sidransky D, (2001) Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res 7: 1982-1986. (Pubitemid 32994835)
13. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG, (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59: 793-797. (Pubitemid 29086728)
14. Fidani P, De Ioris MA, Serra A, De Sio L, Ilari I, Cozza R, et al, (2009) A multimodal strategy based on surgery, radiotherapy, ICE regimen and high dose chemotherapy in atypical teratoid/rhabdoid tumours: a single institution experience. J Neurooncol 92: 177-183.
15. Gardner SL, Asgharzadeh S, Green A, Horn B, McCowage G, Finlay J, (2008) Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors. Pediatr Blood Cancer 51: 235-240. (Pubitemid 351874418)
16. Haberler C, Laggner U, Slavc I, Czech T, Ambros IM, Ambros PF, et al, (2006) Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype. Am J Surg Pathol 30: 1462-1468. (Pubitemid 44655483)
17. Hashizume R, Gupta N, Berger MS, Banerjee A, Prados MD, Ayers-Ringler J, et al, (2010) Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing. Neuro-oncol 12: 366-376.
18. Hasselblatt M, Oyen F, Gesk S, Kordes U, Wrede B, Bergmann M, et al, (2009) Cribriform neuroepithelial tumor (CRINET): a nonrhabdoid ventricular tumor with INI1 loss and relatively favorable prognosis. J Neuropathol Exp Neurol 68: 1249-1255.
19. Hasselblatt M, Fruhwald M, Schneppenheim R, Oyen F, Kordes U, Gesk S, et al, (2010) BRG1 and CRINET: two exceptions to the equation ATRT = inactivation of INI-1 [Abstract]. J Neuropathol Exp Neurol 69: 528.
20. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al, (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003. (Pubitemid 40349502)
21. Hilden JM, Meerbaum S, Burger P, Finlay J, Janss A, Scheithauer BW, et al, (2004) Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol 22: 2877-2884. (Pubitemid 41079907)
22. Hornick JL, Dal Cin P, Fletcher CD, (2009) Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol 33: 542-550.
23. Hulsebos TJ, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F, Wesseling P, (2007) Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet 80: 805-810. (Pubitemid 46564417)
24. Imbalzano AN, Jones SN, (2005) Snf5 tumor suppressor couples chromatin remodeling, checkpoint control, and chromosomal stability. Cancer Cell 7: 294-295. (Pubitemid 40544646)
25. Isakoff MS, Sansam CG, Tamayo P, Subramanian A, Evans JA, Fillmore CM, et al, (2005) Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc Natl Acad Sci USA 102: 17745-17750. (Pubitemid 41803568)
26. Jackson EM, Sievert AJ, Gai X, Hakonarson H, Judkins AR, Tooke L, et al, (2009) Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors. Clin Cancer Res 15: 1923-1930.
27. Judkins AR, Mauger J, Ht A, Rorke LB, Biegel JA, (2004) Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms. Am J Surg Pathol 28: 644-650. (Pubitemid 38579568)
28. Kleinschmidt-DeMasters BK, Meltesen L, McGavran L, Lillehei KO, (2006) Characterization of glioblastomas in young adults. Brain Pathol 16: 273-286.
29. Louis DN, International Agency for Research on Cancer, World Health Organization (2007) In: WHO Classification of Tumours of the Central Nervous System, 4th edn. International Agency for Research on Cancer: Lyon, France.
30. Macedoni-Luksic M, Jereb B, Todorovski L, (2003) Long-term sequelae in children treated for brain tumors: impairments, disability, and handicap. Pediatr Hematol Oncol 20: 89-101. (Pubitemid 36230901)
31. Morgenstern DA, Gibson S, Brown T, Sebire NJ, Anderson J, (2010) Clinical and pathological features of paediatric malignant rhabdoid tumours. Pediatr Blood Cancer 54: 29-34.
32. Mueller W, Nutt CL, Ehrich M, Riemenschneider MJ, von Deimling A, van den Boom D, Louis DN, (2007) Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene 26: 583-593. (Pubitemid 46160971)
33. Muhlisch J, Schwering A, Grotzer M, Vince GH, Roggendorf W, Hagemann C, et al, (2006) Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of childhood. Oncogene 25: 1111-1117. (Pubitemid 43277018)
34. Olson TA, Bayar E, Kosnik E, Hamoudi AB, Klopfenstein KJ, Pieters RS, Ruymann FB, (1995) Successful treatment of disseminated central nervous system malignant rhabdoid tumor. J Pediatr Hematol Oncol 17: 71-75.
35. Patil S, Perry A, Maccollin M, Dong S, Betensky RA, Yeh TH, et al, (2008) Immunohistochemical analysis supports a role for INI1/SMARCB1 in hereditary forms of schwannomas, but not in solitary, sporadic schwannomas. Brain Pathol 18: 517-519.
36. Rorke LB, Packer RJ, Biegel JA, (1996) Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J Neurosurg 85: 56-65. (Pubitemid 26195038)
37. Sunol M, Rovira C, Jou C, Rodriguez E, Cruz O, Cusi V, (2010) Atypical teratoid rhabdoid tumors. clinico-pathologic features in 11 cases [Abstract]. Neuro-oncol 12: ii66.
38. Tekautz TM, Fuller CE, Blaney S, Fouladi M, Broniscer A, Merchant TE, et al, (2005) Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol 23: 1491-1499.
39. Versteege I, Sevenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, et al, (1998) Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394: 203-206. (Pubitemid 28325977)
40. Wagner A, Yachnis A, Powell S, Adesina A, Pearl G, (2009) A posterior fossa embryonal tumor in a 4-year-old male with features of ATRT but without INI-1 mutation [Abstract]. J Neuropathol Exp Neurol 68: 588.
41. Wharton SB, Wardle C, Ironside JW, Wallace WH, Royds JA, Hammond DW, (2003) Comparative genomic hybridization and pathological findings in atypical teratoid/rhabdoid tumour of the central nervous system. Neuropathol Appl Neurobiol 29: 254-261. (Pubitemid 36718173)
42. Zhang F, Tan L, Wainwright LM, Bartolomei MS, Biegel JA, (2002) No evidence for hypermethylation of the hSNF5/INI1 promoter in pediatric rhabdoid tumors. Genes Chromosomes Cancer 34: 398-405. (Pubitemid 34787461)
43. Zimmerman MA, Goumnerova LC, Proctor M, Scott RM, Marcus K, Pomeroy SL, et al, (2005) Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumor. J Neurooncol 72: 77-84. (Pubitemid 41149181)
44. Zou XP, Zhang B, Zhang XQ, Chen M, Cao J, Liu WJ, (2009) Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions. Hum Pathol 40: 1534-1542.